DxS Ltd, a UK-based personalised medicine company, has appointed David Jackson as its new vice president for business development and licensing in the US. He also has responsibility for planning and executing deals for the company’s companion diagnostics business.
Dr Jackson was most recently executive vice president at Response Genetics Inc and president and chief operating officer at CryoFluor Therapeutics LLC, both in the US. He holds a PhD in physiology and medicine from the Boston University School of Medicine. He is trained as a US patent agent and holds several US securities licenses.
Copyright 2009 Evernow Publishing Ltd